News

AstraZeneca’s camizestrant gains momentum, but questions remain as first-line therapy
The trial evaluated the effectiveness of AstraZeneca’s camizestrant, an investigational next-generation oral selective ...
Arvinas price target lowered to $24 from $67 at Piper Sandler
Piper Sandler lowered the firm’s price target on Arvinas (ARVN) to $24 from $67 on narrowed vepdegestrant ESR1-mutant mBC approval, while ...